Please login to the form below

Not currently logged in
Email:
Password:

NSCLC

This page shows the latest NSCLC news and features for those working in and with pharma, biotech and healthcare.

Merck’s Keytruda meets survival challenge in NSCLC

Merck’s Keytruda meets survival challenge in NSCLC

advanced, non-squamous NSCLC was significantly improved with Keytruda (pembrolizumab) plus chemo, with the risk of death 51% lower than with chemo alone. ... the response rate compared to chemotherapy in first-line NSCLC patients with a high tumour

Latest news

More from news
Approximately 100 fully matching, plus 304 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Though its main competitor, BMS’Opdivo, was first to the NSCLC market, Merck’s frontline trial for Keytruda succeeded whereas Opdivo’s failed.

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.

  • Pharma deals during October 2014 Pharma deals during October 2014

    This month's big pharma collaborations are in oncology, firstly where Novartis and BMS have entered a clinical collaboration for a combination of drugs in non-small cell lung cancer (NSCLC). ... Zykadia is approved in the US for patients with anaplastic

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    Xalkori: Symptom improvement and quality of life gains add benefit. In the case of Xalkori (crizotinib), Pfizer's product targeting a subsegment of non-small cell lung cancer (NSCLC) in which ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    2 trials for NSCLC, and tremelimumab, an anti-CTLA4 MAb in phase 2 for the rare cancer mesothelioma. “ ... This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. “

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics